Aminooxy-Acetic Acid Inhibits Experimental Autoimmune Uveitis by Modulating the Balance between Effector and Regulatory Lymphocyte Subsets

Author(s): Suyin Mei, Yike Huang, Na Li, Zongren Xu, Jing Xu, Qinjin Dai, Juan Wu, Aize Kijlstra, Peizeng Yang, Shengping Hou*

Journal Name: Current Molecular Medicine

Volume 20 , Issue 8 , 2020


  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Abstract:

Purpose: A small molecular compound, aminooxy-acetic acid (AOA), has been shown to modulate experimental autoimmune encephalomyelitis (EAE). The current study was designed to investigate whether AOA has a similar effect on the development of experimental autoimmune uveitis (EAU) and to further explore underlying mechanisms of this drug.

Methods: EAU was induced in C57BL/6J mice by immunization with interphotoreceptor retinoid-binding protein peptide 651-670 (IRBP 651-670). AOA (500μg or 750μg) or vehicle was administered by intraperitoneal injection from day 10 to 14 after EAU induction. The severity was assessed by clinical and histological scores. The integrity of the blood retinal barrier was detected with Evans Blue. Frequencies of splenic Th1, Th17 and Foxp3+ Treg cells were examined by flow cytometry. The production of cytokines was tested by ELISA. The mRNA expression of IL-17, IFN-γ and IL-10 was detected by RT-PCR. The expression of p-Stat1 and NF-κB was detected by Western Blotting.

Results: AOA was found to markedly inhibit the severity of EAU, as determined by clinical and histopathological examinations. AOA can relieve the leakage of blood retinal barrier (BRB). Functional studies found a decreased frequency of Th1 and Th17 cells and an increased frequency of Treg cells in EAU mice as compared with controls. Further studies showed that AOA not only downregulated the production of the proinflammatory cytokines including IFN-γ and IL-17 but also upregulated the expression of an anti-inflammatory cytokine such as IL-10, which might be caused by inhibiting the expressions of p-Stat1 and NF-κB.

Conclusion: This study shows that AOA inhibits the severity and development of EAU by modulating the balance between regulatory and pathogenic lymphocyte subsets.

Keywords: Experimental autoimmune uveitis, aminooxy-acetic acid (AOA), Th17 cell, Th1 cell, Treg cell, Uveitis.

[1]
Du L, Kijlstra A, Yang P. Immune response genes in uveitis. Ocul Immunol Inflamm 2009; 17(4): 249-56.
[http://dx.doi.org/10.1080/09273940902999356] [PMID: 19657978]
[2]
Huang Y, He J, Liang H, et al. Aryl Hydrocarbon Receptor Regulates Apoptosis and Inflammation in a Murine Model of Experimental Autoimmune Uveitis. Front Immunol 2018; 9: 1713.
[http://dx.doi.org/10.3389/fimmu.2018.01713] [PMID: 30090104]
[3]
Qiu Y, Tao L, Zheng S, et al. AAV8-Mediated Angiotensin-Converting Enzyme 2 Gene Delivery Prevents Experimental Autoimmune Uveitis by Regulating MAPK, NF-κB and STAT3 Pathways. Sci Rep 2016; 6: 31912.
[http://dx.doi.org/10.1038/srep31912] [PMID: 27558087]
[4]
Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol 2013; 23(5): 705-17.
[http://dx.doi.org/10.5301/ejo.5000278] [PMID: 23661536]
[5]
Hou S, Liao D, Zhang J, et al. Genetic variations of IL17F and IL23A show associations with Behçet’s disease and Vogt-Koyanagi-Harada syndrome. Ophthalmology 2015; 122(3): 518-23.
[http://dx.doi.org/10.1016/j.ophtha.2014.09.025] [PMID: 25439430]
[6]
Rao NA. Uveitis in developing countries. Indian J Ophthalmol 2013; 61(6): 253-4.
[http://dx.doi.org/10.4103/0301-4738.114090] [PMID: 23803475]
[7]
Meng X, Fang S, Zhang Z, et al. Preventive effect of chrysin on experimental autoimmune uveitis triggered by injection of human IRBP peptide 1-20 in mice. Cell Mol Immunol 2017; 14(8): 702-11.
[http://dx.doi.org/10.1038/cmi.2015.107] [PMID: 26996065]
[8]
Selmi C. Diagnosis and classification of autoimmune uveitis. Autoimmun Rev 2014; 13(4-5): 591-4.
[http://dx.doi.org/10.1016/j.autrev.2014.01.006] [PMID: 24424168]
[9]
Chen X, Su W, Wan T, et al. Sodium butyrate regulates Th17/Treg cell balance to ameliorate uveitis via the Nrf2/HO-1 pathway. Biochem Pharmacol 2017; 142: 111-9.
[http://dx.doi.org/10.1016/j.bcp.2017.06.136] [PMID: 28684304]
[10]
Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014; 13(6): 668-77.
[http://dx.doi.org/10.1016/j.autrev.2013.12.004] [PMID: 24418308]
[11]
Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 2012; 11(10): 687-98.
[http://dx.doi.org/10.1016/j.autrev.2011.11.026] [PMID: 22197900]
[12]
Agarwal RK, Silver PB, Caspi RR. Rodent models of experimental autoimmune uveitis. Methods Mol Biol 2012; 900: 443-69.
[http://dx.doi.org/10.1007/978-1-60761-720-4_22] [PMID: 22933083]
[13]
Bousquet E, Camelo S, Leroux les, Jardins G, et al. Protective effect of intravitreal administration of tresperimus, an immunosuppressive drug, on experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2011; 52(8): 5414-23.
[http://dx.doi.org/10.1167/iovs.10-6740] [PMID: 21666239]
[14]
Klimova A, Seidler Stangova P, Svozilkova P, Forrester JV, Klaska I, Heissigerova J. The critical points in induction of experimental autoimmune uveitis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016; 160(1): 140-2.
[http://dx.doi.org/10.5507/bp.2015.056] [PMID: 26558361]
[15]
Servat JJ, Mears KA, Black EH, Huang JJ. Biological agents for the treatment of uveitis. Expert Opin Biol Ther 2012; 12(3): 311-28.
[http://dx.doi.org/10.1517/14712598.2012.658366] [PMID: 22339439]
[16]
Gomes Bittencourt M, Sepah YJ, Do DV, et al. New treatment options for noninfectious uveitis. Dev Ophthalmol 2012; 51: 134-61.
[http://dx.doi.org/10.1159/000336338] [PMID: 22517211]
[17]
Xu T, Stewart KM, Wang X, et al. Metabolic control of TH17 and induced Treg cell balance by an epigenetic mechanism. Nature 2017; 548(7666): 228-33.
[http://dx.doi.org/10.1038/nature23475] [PMID: 28783731]
[18]
Loo TT, Gao Y, Lazarevic V. Transcriptional regulation of CD4+ TH cells that mediate tissue inflammation. J Leukoc Biol 2018; 104(6): 1069-85.
[http://dx.doi.org/10.1002/JLB.1RI0418-152RR] [PMID: 30145844]
[19]
Hirahara K, Onodera A, Villarino AV, et al. Asymmetric Action of STAT Transcription Factors Drives Transcriptional Outputs and Cytokine Specificity. Immunity 2015; 42(5): 877-89.
[http://dx.doi.org/10.1016/j.immuni.2015.04.014] [PMID: 25992861]
[20]
Hirahara K, Schwartz D, Gadina M, Kanno Y, O’Shea JJ. Targeting cytokine signaling in autoimmunity: back to the future and beyond. Curr Opin Immunol 2016; 43: 89-97.
[http://dx.doi.org/10.1016/j.coi.2016.10.001] [PMID: 27821272]
[21]
Nakamura YK, Janowitz C, Metea C, et al. Short chain fatty acids ameliorate immune-mediated uveitis partially by altering migration of lymphocytes from the intestine. Sci Rep 2017; 7(1): 11745.
[http://dx.doi.org/10.1038/s41598-017-12163-3] [PMID: 28924192]
[22]
Harimoto K, Ito M, Karasawa Y, Sakurai Y, Takeuchi M. Evaluation of mouse experimental autoimmune uveoretinitis by spectral domain optical coherence tomography. Br J Ophthalmol 2014; 98(6): 808-12.
[http://dx.doi.org/10.1136/bjophthalmol-2013-304421] [PMID: 24574437]
[23]
Relvas LJ, Makhoul M, Dewispelaere R, et al. P2Y2R deficiency attenuates experimental autoimmune uveitis development. PLoS One 2015; 10(2)e0116518
[http://dx.doi.org/10.1371/journal.pone.0116518] [PMID: 25692550]
[24]
Copland DA, Liu J, Schewitz-Bowers LP, et al. Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier. Am J Pathol 2012; 180(2): 672-81.
[http://dx.doi.org/10.1016/j.ajpath.2011.10.008] [PMID: 22119714]
[25]
Chen RY, Fan YM, Zhang Q, et al. Estradiol inhibits Th17 cell differentiation through inhibition of RORγT transcription by recruiting the ERα/REA complex to estrogen response elements of the RORγT promoter. J Immunol 2015; 194(8): 4019-28.
[http://dx.doi.org/10.4049/jimmunol.1400806] [PMID: 25769926]
[26]
McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007; 8(12): 1390-7.
[http://dx.doi.org/10.1038/ni1539] [PMID: 17994024]
[27]
Wandu WS, Tan C, Ogbeifun O, et al. Leucine-Rich Repeat Kinase 2 (Lrrk2) Deficiency Diminishes the Development of Experimental Autoimmune Uveitis (EAU) and the Adaptive Immune Response. PLoS One 2015; 10(6)e0128906
[http://dx.doi.org/10.1371/journal.pone.0128906] [PMID: 26067490]
[28]
Almeida L, Lochner M, Berod L, Sparwasser T. Metabolic pathways in T cell activation and lineage differentiation. Semin Immunol 2016; 28(5): 514-24.
[http://dx.doi.org/10.1016/j.smim.2016.10.009] [PMID: 27825556]
[29]
Patel CH, Powell JD. Targeting T cell metabolism to regulate T cell activation, differentiation and function in disease. Curr Opin Immunol 2017; 46: 82-8.
[http://dx.doi.org/10.1016/j.coi.2017.04.006] [PMID: 28521236]
[30]
Perry TL, Wright JM, Hansen S, Allan BM, Baird PA, MacLeod PM. Failure of aminooxyacetic acid therapy in Huntington disease. Neurology 1980; 30(7 Pt 1): 772-5.
[http://dx.doi.org/10.1212/WNL.30.7.772] [PMID: 6446691]
[31]
Klaska IP, Forrester JV. Mouse models of autoimmune uveitis. Curr Pharm Des 2015; 21(18): 2453-67.
[http://dx.doi.org/10.2174/1381612821666150316122928] [PMID: 25777760]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 8
Year: 2020
Page: [624 - 632]
Pages: 9
DOI: 10.2174/1566524020666200211112219
Price: $65

Article Metrics

PDF: 45
HTML: 3